GleamWall
中文EN

ACET Adicet Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1720580 · Fiscal year ends 12/26

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY20.9%
TTM EPS YoY78.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-85.9%
ROA-67.5%
ROIC (approx.)-97.0%
Asset turnover—

Leverage & solvency

Liabilities / assets20.4%
Debt / equity0.00x
Current ratio6.09x
Interest coverage-1,038.62x

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$15.63M$18.45M$17.49M$25.04M$22.85M$28.42M$22.81M$23.27M
SG&A expense$4.17M$3.85M$4.08M$6.85M$5.10M$3.97M$7.07M$7.47M
Operating income-$19.80M-$22.30M-$21.57M-$31.89M-$27.95M-$32.39M-$29.89M-$30.74M
Interest expense$23,000$22,000$23,000$24,000$12,000$0$0$1,000
Pretax income-$18.88M-$21.21M-$20.24M-$30.52M-$26.86M-$31.22M-$28.21M-$28.73M
Income tax$1,000$143,000$0$0$0$0$0$0
Net income-$18.88M-$21.36M-$20.24M-$30.52M-$26.86M-$31.22M-$28.21M-$28.73M
EBITDA-$18.80M-$21.10M-$20.23M-$30.41M-$26.35M-$30.74M-$28.29M-$29.12M
EPS (basic)-1.76-1.99-1.88—-4.72-5.48-4.96—
EPS (diluted)-1.76-1.99-1.88—-4.72-5.48-4.96—
Weighted avg. shares (diluted)10.75M10.75M10.74M—5.69M5.69M5.69M—
Balance sheet
Cash & equivalents$27.11M$33.13M$36.24M$38.92M$29.10M$34.72M$28.13M$59.40M
Current assets$103.44M$120.76M$140.07M$160.93M$106.49M$127.74M$153.56M$180.14M
PP&E, net$13.07M$14.03M$15.18M$16.53M$17.99M$19.55M$21.11M$22.52M
Total assets$128.95M$148.17M$169.38M$192.35M$140.48M$162.97M$191.27M$220.22M
Current liabilities$17.00M$18.00M$18.30M$21.53M$18.94M$17.08M$16.45M$19.39M
Total liabilities$26.25M$28.03M$29.32M$33.15M$31.34M$29.60M$29.82M$33.61M
Shareholders' equity$102.70M$120.14M$140.06M$159.21M$109.14M$133.37M$161.45M$186.61M
Shares outstanding9.36M9.36M9.60M9.59M83.25M83.25M82.71M5.16M
Cash flow statement
Operating cash flow-$17.92M-$19.82M-$21.49M-$20.91M-$22.31M-$26.63M-$25.40M-$24.10M
Capital expenditure$56,000$202,000$37,000-$10,000$209,000$47,000$1.49M$176,000
Free cash flow-$17.98M-$20.02M-$21.53M-$20.90M-$22.52M-$26.68M-$26.89M-$24.28M
Investing cash flow$11.60M$16.65M$18.88M-$44.53M$16.84M$32.95M-$2.86M-$22.12M
Financing cash flow$1,000$58,000-$65,000$75.23M-$150,000$267,000-$104,000$137,000
Depreciation & amortization$1.00M$1.20M$1.34M$1.47M$1.60M$1.66M$1.60M$1.62M
Stock-based compensation$1.50M$1.40M$1.30M$5.65M$2.50M$2.90M$3.18M$3.77M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.